4509

Early detection of ovarian cancer might improve clinical outcome. Some studies have shown the hemoglobin as a new group of tumor markers for ovarian cancer. We have previously reported the identification of three ovarian cancer biomarker panels comprised of SELDI-TOF-MS peaks representing 37 differentially expressed serum proteins for the diagnosis of ovarian cancer. We hypothesized that a multiple tumor markers including hemoglobin might provide high diagnosic power. To evaluate the diagnostic utilities of multiple tumor markers, we used multiplexed liquid assay system. Hemoglobin, haptoglobin, CA125, SLPI, ostopontin, Apo E, EGF, IL6 and MCP-1 showed significant differences in serum concentration between ovarian cancer and control. (P<0.05) Nine makers showed significant differences in serum concentrations between ovarian cancer and control groups. Sensitivity for Hemoglobin, Haptoglobin and CA125 for ovarian cancer was 67.4%, 66.7%, 67.2%. Specificity for Hemoglobin, Haptoglobin and CA125 for ovarian cancer was 95.0%, 95.2% and 74.1%. False positive for Hemoglobin, Haptoglobin and CA125 for ovarian cancer was 3.1%, 30.0% and 25.6%. False negative for Hemoglobin, Haptoglobin and CA125 for ovarian cancer was 44.1%, 44.4% and 30.2%. Accuracy for Hemoglobin, Haptoglobin and CA125 for ovarian cancer was 75.8 %, 75.4% and 80.2%. The receiver operator characteristic curve created using the combination of markers produced sensitivities between 85% and 95% in the area of 80% to 85% specificity, whereas the receiver operator characteristic curve for CA-125 alone resulted in sensitivities of 65% to 80%. The presented data show that simultaneous testing of a multiple tumor markers and CA125 using LabMap technology may present a promising approaching for ovarian cancer detection.

[Proc Amer Assoc Cancer Res, Volume 47, 2006]